Product Description
For Chronic Obstructive Pulmonary Disease (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00640484)
Mechanisms of Action: ADRB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Turkey
Approved Indications: None
Known Adverse Events: None
Company: Chiesi
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Asthma|Chronic Obstructive Pulmonary Disease
Phase 1: Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
OHRQoL in down syndrome | N/A |
Not yet recruiting |
Cystic Fibrosis|Asthma |
2018-06-30 |
|
2009-013759-32 | P2 |
Completed |
Asthma |
2010-06-23 |
|
2008-001773-15 | P2 |
Completed |
Asthma |
2009-01-06 |
|
CT14 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2008-12-01 |